Literature DB >> 17460703

Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab.

B Royer, I Vaida, A Etienne, R Garidi, G Damaj, J P Marolleau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17460703     DOI： 10.1038/sj.leu.2404713

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

Review 1.  Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 2.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

Review 3.  Immunotherapy treatments of warm autoimmune hemolytic anemia.

Authors:  Bainan Liu; Wangang Gu
Journal:  Clin Dev Immunol       Date:  2013-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.